Study of Biomarkers in DNA Samples From Patients With Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia
NCT ID: NCT01005277
Last Updated: 2022-07-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
2000 participants
OBSERVATIONAL
2002-04-17
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Biomarkers in Blood and Bone Marrow Samples From Patients With Acute Lymphoblastic Leukemia
NCT01284010
Biomarkers in Tissue Samples From Young Patients With Acute Myeloid Leukemia
NCT01229956
Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia
NCT00900224
Biomarker Study in Tissue Samples From Patients With Acute Myeloid Leukemia
NCT01232842
DNA Analysis of Bone Marrow and Blood Samples From Young Patients With Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
NCT00899652
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
I. Collect DNA samples from patients with cytogenetically, well characterized, and uniformly treated acute lymphoblastic leukemia or acute myeloid leukemia for use in analysis of a wide range of host factors influencing etiology and outcome of the disease.
II. Identify host factors that can be determined at onset of treatment to predict outcome of chemotherapy, and thus modify the therapy administered.
OUTLINE:
Previously collected DNA samples are analyzed for polymorphisms at a variety of loci. Gene expression and expression profiles are correlated with genotype and therapy outcomes.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Ancillary-Correlative (genetic polymorphisms)
Previously collected DNA samples are analyzed for polymorphisms at a variety of loci. Gene expression and expression profiles are correlated with genotype and therapy outcomes.
Laboratory Biomarker Analysis
Correlative studies
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Laboratory Biomarker Analysis
Correlative studies
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Infants with acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML)
* Patients with pre-B ALL, including responders vs non-responders in selected genotypes \[hyperdiploid, hypodiploid, t(12;21), t(9;22), t(1;19), and t(4;11)\] and responders and non-responders regardless of genotype
* Pediatric patients with AML registered on POG-9421
* Adult patients with ALL, including t(8.21), inv(16), t(15;17), complex cytogenetics, and secondary AML
* Pediatric patients with relapsed ALL enrolled on COG-AALL01P2
* Pediatric patients enrolled on COG-9900 and other CCG or POG trials
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Children's Oncology Group
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Stella Davies
Role: PRINCIPAL_INVESTIGATOR
Children's Oncology Group
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Childrens Oncology Group
Philadelphia, Pennsylvania, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2009-00325
Identifier Type: REGISTRY
Identifier Source: secondary_id
CDR0000271322
Identifier Type: -
Identifier Source: secondary_id
COG-ABTR02B1
Identifier Type: -
Identifier Source: secondary_id
ABTR02B1
Identifier Type: -
Identifier Source: secondary_id
ABTR02B1
Identifier Type: OTHER
Identifier Source: secondary_id
ABTR02B1
Identifier Type: OTHER
Identifier Source: secondary_id
ABTR02B1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.